Primary Site >> Colorectal Cancer
Gene >> PIK3CA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: A novel mitogenic signaling pathway of bradykinin in the human colon carcinoma cell line SW-480 involves sequential activation of a Gq/11 protein, phosphatidylinositol 3-kinase beta, and protein kinase Cepsilon. PMID: 9822674 |
Ref: A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells. PMID: 11042696 Ref: Leptin promotes invasiveness of kidney and colonic epithelial cells via phosphoinositide 3-kinase-, rho-, and rac-dependent signaling pathways. PMID: 11053255 |
Ref: Phosphatidylinositol 3-kinase mediates proliferative signals in intestinal epithelial cells. PMID: 12970141 |
Ref: Involvement of the PI 3-kinase signaling pathway in progression of colon adenocarcinoma. PMID: 14578160 Ref: Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. PMID: 15289301 Ref: Inhibition of alpha5 integrin decreases PI3K activation and cell adhesion of human colon cancers. PMID: 15300173 Ref: Mutation of the PIK3CA gene in ovarian and breast cancer. PMID: 15520168 |
Ref: PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. PMID: 15608678 Ref: TNF-alpha activates MUC2 transcription via NF-kappaB but inhibits via JNK activation. PMID: 15665513 Ref: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. PMID: 15863375 Ref: Functional analysis of PIK3CA gene mutations in human colorectal cancer. PMID: 15930273 Ref: Mutant PIK3CA promotes cell growth and invasion of human cancer cells. PMID: 15950905 Ref: The prevalence of PIK3CA mutations in gastric and colon cancer. PMID: 15994075 Ref: Comparison of phosphatidylinositol-3-kinase signalling within a panel of human colorectal cancer cell lines with mutant or wild-type PIK3CA. PMID: 16150444 Ref: Somatic mutation and gain of copy number of PIK3CA in human breast cancer. PMID: 16168105 |
Ref: Somatic mutations of the ERBB4 kinase domain in human cancers. PMID: 16187281 Ref: Oncogenic PI3K and its role in cancer. PMID: 16357568 Ref: Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines. PMID: 16376301 Ref: Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. PMID: 16397024 Ref: Hypoxic regulation of vascular endothelial growth factor through the induction of phosphatidylinositol 3-kinase/Rho/ROCK and c-Myc. PMID: 16543245 Ref: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. PMID: 16618717 Ref: Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma. PMID: 16772787 Ref: Improved marker combination for detection of de novo genetic variation and aberrant DNA in colorectal neoplasia. PMID: 17082247 |
Ref: Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. PMID: 17314276 Ref: Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis. PMID: 17363507 Ref: Mutations of the PIK3CA gene in hereditary colorectal cancers. PMID: 17546593 Ref: Mutant PIK3CA-bearing colon cancer cells display increased metastasis in an orthotopic model. PMID: 17575153 Ref: PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. PMID: 17590872 |
Ref: Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer. PMID: 17990317 Ref: PIK3CA cancer mutations display gender and tissue specificity patterns. PMID: 18022911 Ref: Deoxycholyltaurine rescues human colon cancer cells from apoptosis by activating EGFR-dependent PI3K/Akt signaling. PMID: 18064605 Ref: Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population. PMID: 18193083 Ref: PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. PMID: 18339877 Ref: Multiplexed assays for detection of mutations in PIK3CA. PMID: 18375489 Ref: Defining the blueprint of the cancer genome. PMID: 18495658 Ref: PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. PMID: 18516290 Ref: In vitro differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 BRAF mutation. PMID: 18524847 Ref: Genetic alterations in colorectal cancers with demethylation of insulin-like growth factor II. PMID: 18619647 Ref: High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. PMID: 18628094 Ref: Somatic oncogenic mutations, benign skin lesions and cancer progression: where to look next? PMID: 18728396 Ref: PTEN-deficient cancers depend on PIK3CB. PMID: 18755892 Ref: BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis? PMID: 18782444 Ref: The transforming functions of PI3-kinase-gamma are linked to disruption of intercellular adhesion and promotion of cancer cell invasion. PMID: 18837901 Ref: PIK3CA gene mutations in breast carcinoma in Malaysian patients. PMID: 19027487 |
Ref: Molecular pathology of endometrial carcinoma: practical aspects from the diagnostic and therapeutic viewpoints. PMID: 18977806 Ref: Endometrial cancer and somatic G>T KRAS transversion in patients with constitutional MUTYH biallelic mutations. PMID: 18980800 Ref: Clinical, pathologic, and molecular features of early-onset colorectal carcinoma. PMID: 19047896 Ref: JC virus T-antigen in colorectal cancer is associated with p53 expression and chromosomal instability, independent of CpG island methylator phenotype. PMID: 19107235 Ref: Colorectal cancer expression of peroxisome proliferator-activated receptor gamma (PPARG, PPARgamma) is associated with good prognosis. PMID: 19186181 Ref: Knockin of mutant PIK3CA activates multiple oncogenic pathways. PMID: 19196980 Ref: PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. PMID: 19223544 Ref: Knockdown of Ron kinase inhibits mutant phosphatidylinositol 3-kinase and reduces metastasis in human colon carcinoma. PMID: 19224914 Ref: PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. PMID: 19237633 Ref: Aurora-A expression is independently associated with chromosomal instability in colorectal cancer. PMID: 19412426 Ref: SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. PMID: 19430421 Ref: DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer. PMID: 19470733 Ref: Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors. PMID: 19492075 Ref: A cohort study of p27 localization in colon cancer, body mass index, and patient survival. PMID: 19505918 Ref: Blocking phosphoinositide 3-kinase activity in colorectal cancer cells reduces proliferation but does not increase apoptosis alone or in combination with cytotoxic drugs. PMID: 19509113 Ref: A cohort study of STMN1 expression in colorectal cancer: body mass index and prognosis. PMID: 19513025 Ref: Clinical biomarkers in oncology: focus on colorectal cancer. PMID: 19537845 Ref: Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer. PMID: 19584150 Ref: [Status of components in EGFR-related signal transduction as predictive markers for anti-EGFR antibody therapy in colorectal cancer treatment]. PMID: 19620792 Ref: A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers. PMID: 19686742 Ref: Frequent PIK3CA gene amplification and its clinical significance in colorectal cancer. PMID: 19697359 Ref: Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers. PMID: 19704056 Ref: p21 expression in colon cancer and modifying effects of patient age and body mass index on prognosis. PMID: 19723919 Ref: Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. PMID: 19738166 Ref: An A13 repeat within the 3'-untranslated region of epidermal growth factor receptor (EGFR) is frequently mutated in microsatellite instability colon cancers and is associated with increased EGFR expression. PMID: 19789347 Ref: Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer. PMID: 19789368 Ref: Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PMID: 19806185 Ref: PIK3CA mutations predict local recurrences in rectal cancer patients. PMID: 19903786 Ref: Getting knit-PI3Ky: PIK3CA mutation status to direct multimodality therapy? PMID: 19903790 Ref: Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer. PMID: 19917537 Ref: Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. PMID: 19962665 Ref: The dark side of the moon: the PI3K/PTEN/AKT pathway in colorectal carcinoma. PMID: 20130434 Ref: [Biomarkers and anti-EGFR therapies for KRAS wild-type tumors in metastatic colorectal cancer patients]. PMID: 20432670 |
Ref: Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer. PMID: 19731079 Ref: CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival. PMID: 19790197 Ref: Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients. PMID: 20056651 Ref: Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes. PMID: 20098682 Ref: Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. PMID: 20100961 Ref: Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. PMID: 20103678 Ref: PTGER2 overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype. PMID: 20200425 Ref: A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. PMID: 20233444 Ref: HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. PMID: 20363910 Ref: Oncogenic mutations as predictive factors in colorectal cancer. PMID: 20383189 Ref: Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. PMID: 20413299 Ref: Recent patents and advances in genomic biomarker discovery for colorectal cancers. PMID: 20426761 Ref: Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors. PMID: 20507599 Ref: Tuberous sclerosis complex 2 (TSC2) regulates cell migration and polarity through activation of CDC42 and RAC1. PMID: 20530489 Ref: The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy. PMID: 20551061 Ref: Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1. PMID: 20622004 Ref: Gene mutations in epidermal growth factor receptor signaling network and their association with survival in Chinese patients with metastatic colorectal cancers. PMID: 20652941 Ref: Hypomethylation of the IGF2 DMR in colorectal tumors, detected by bisulfite pyrosequencing, is associated with poor prognosis. PMID: 20682317 Ref: Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. PMID: 20713879 Ref: KRAS mutation testing of colorectal cancer for anti-EGFR therapy: dogmas versus evidence. PMID: 20718705 Ref: NRAS mutations are rare in colorectal cancer. PMID: 20736745 Ref: Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer. PMID: 20808308 Ref: Cathepsin B expression and survival in colon cancer: implications for molecular detection of neoplasia. PMID: 20833970 Ref: Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. PMID: 20927778 Ref: Colorectal cancer: cetuximab, KRAS, BRAF, PIK3CA mutations and beyond. PMID: 20932136 Ref: The p110alpha and p110beta isoforms of class I phosphatidylinositol 3-kinase are involved in toll-like receptor 5 signaling in epithelial cells. PMID: 20953381 Ref: Activation of signal pathways and the resistance to anti-EGFR treatment in colorectal cancer. PMID: 21053280 Ref: DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset. PMID: 21103049 Ref: Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer. PMID: 21139621 Ref: Predictive and prognostic factors in the complex treatment of patients with colorectal cancer. PMID: 21163770 Ref: Do rectal cancer patients with PIK3CA mutations benefit from preoperative radiotherapy with regard to local recurrences? PMID: 21169263 |
Ref: Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review. PMID: 20473920 Ref: PIK3CA mutations in KRAS and BRAF wild type colorectal cancer patients. A study of Spanish population. PMID: 20571907 Ref: Genetic variation in RPS6KA1, RPS6KA2, RPS6KB1, RPS6KB2, and PDK1 and risk of colon or rectal cancer. PMID: 21035469 Ref: Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. PMID: 21036793 Ref: MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers. PMID: 21140203 Ref: KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. PMID: 21163703 Ref: Effect of classification based on combination of mutation and methylation in colorectal cancer prognosis. PMID: 21174064 Ref: PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. PMID: 21216929 Ref: KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. PMID: 21239505 Ref: Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in >/= 2 line cetuximab-based therapy of colorectal cancer patients. PMID: 21283802 Ref: BRAF p.Val600Glu (V600E) somatic mutation is mainly associated with MSS phenotype in metastatic colorectal cancer. PMID: 21289333 Ref: STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers. PMID: 21310826 Ref: Analysis of K-ras, BRAF, and PIK3CA mutations in laterally-spreading tumors of the colorectum. PMID: 21332555 Ref: KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer. PMID: 21424126 Ref: Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers. PMID: 21425139 Ref: Molecular predictors of response to chemotherapy in colorectal cancer. PMID: 21427555 Ref: Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. PMID: 21521850 Ref: Detection of tumor DNA at the margins of colorectal cancer liver metastasis. PMID: 21531819 Ref: Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. PMID: 21632860 Ref: The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy. PMID: 21671463 Ref: Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. PMID: 21673091 Ref: Molecular alterations associated with liver metastases development in colorectal cancer patients. PMID: 21673680 Ref: KRAS, NRAS, PIK3CA exon 20, and BRAF genotypes in synchronous and metachronous primary colorectal cancers diagnostic and therapeutic implications. PMID: 21704278 Ref: Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours. PMID: 21712828 Ref: Development of molecular biomarkers in individualized treatment of colorectal cancer. PMID: 21729679 Ref: Selective BRAFV600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance. PMID: 21738740 Ref: Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review. PMID: 21742964 Ref: [Predictive biomarkers of anti-EGFR monoclonal anti-body in colorectal cancer]. PMID: 21772090 Ref: Glucose metabolism measured by [(1)(8)F]fluorodeoxyglucose positron emission tomography is independent of PTEN/AKT status in human colon carcinoma cells. PMID: 21804920 Ref: [KRAS mutation test]. PMID: 21815483 Ref: Cancer immunology--analysis of host and tumor factors for personalized medicine. PMID: 21826083 Ref: PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PMID: 21829508 Ref: PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis. PMID: 21830111 Ref: TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers. PMID: 21949851 Ref: The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer. PMID: 21966435 Ref: Diet and colorectal cancer: analysis of a candidate pathway using SNPS, haplotypes, and multi-gene assessment. PMID: 21999454 Ref: Chromothripsis is a common mechanism driving genomic rearrangements in primary and metastatic colorectal cancer. PMID: 22014273 Ref: Frequency of KRAS, BRAF, and PIK3CA mutations in advanced colorectal cancers: Comparison of peptide nucleic acid-mediated PCR clamping and direct sequencing in formalin-fixed, paraffin-embedded tissue. PMID: 22070922 Ref: [Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer]. PMID: 22145213 Ref: A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. PMID: 22586653 |
Ref: Increased frequency of 20q gain and copy-neutral loss of heterozygosity in mismatch repair proficient familial colorectal carcinomas. PMID: 21445971 Ref: Studies on the expression patterns of class I PI3K catalytic subunits and its prognostic significance in colorectal cancer. PMID: 21910030 Ref: Oncogenic PIK3CA mutations in colorectal cancers and polyps. PMID: 21932420 Ref: Tumor TP53 expression status, body mass index and prognosis in colorectal cancer. PMID: 22038927 Ref: PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. PMID: 22039088 Ref: Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212. PMID: 22169769 Ref: Prognostic significance and molecular associations of tumor growth pattern in colorectal cancer. PMID: 22189472 Ref: Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients:implications for cancer therapy. PMID: 22229245 Ref: Emerging role of cetuximab in the treatment of colorectal cancer. PMID: 22264223 Ref: Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer. PMID: 22270257 Ref: PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. PMID: 22285706 Ref: Colorectal serrated adenocarcinoma shows a different profile of oncogene mutations, MSI status and DNA repair protein expression compared to conventional and sporadic MSI-H carcinomas. PMID: 22287190 Ref: Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. PMID: 22357840 Ref: Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. PMID: 22392911 Ref: Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. PMID: 22427238 Ref: Predictors of lymph node count in colorectal cancer resections: data from US nationwide prospective cohort studies. PMID: 22508672 Ref: Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines. PMID: 22543857 Ref: Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib. PMID: 22553375 Ref: Genetic alterations in colorectal cancer. PMID: 22574233 Ref: Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population. PMID: 22579930 Ref: KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer. PMID: 22586484 Ref: Utility of cell-free tumour DNA for post-surgical follow-up of colorectal cancer patients. PMID: 22593440 Ref: Comparative genomic analysis of primary versus metastatic colorectal carcinomas. PMID: 22665543 Ref: KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. PMID: 22675430 Ref: Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA. PMID: 22696593 Ref: Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials. PMID: 22723336 Ref: PIK3CA mutation and methylation influences the outcome of colorectal cancer. PMID: 22740953 Ref: Acquired/intratumoral mutation of KRAS during metastatic progression of colorectal carcinogenesis. PMID: 22740969 Ref: Killing of Kras-mutant colon cancer cells via Rac-independent actin remodeling by the betaGBP cytokine, a physiological PI3K inhibitor therapeutically effective in vivo. PMID: 22752425 Ref: Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. PMID: 22753589 Ref: Phosphoinositide-3-kinase, catalytic, alpha polypeptide RNA interference inhibits growth of colon cancer cell SW948. PMID: 22807617 Ref: Comprehensive molecular characterization of human colon and rectal cancer. PMID: 22810696 Ref: Novel small interfering RNA cotargeting strategy as treatment for colorectal cancer. PMID: 22828149 Ref: Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer. PMID: 22840368 Ref: PI3K expression and PIK3CA mutations are related to colorectal cancer metastases. PMID: 22851869 Ref: The utility of diagnostic biopsy specimens for predictive molecular testing in colorectal cancer. PMID: 22882224 Ref: Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations. PMID: 22911782 Ref: Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. PMID: 22927482 Ref: Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia. PMID: 22931052 Ref: High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS , BRAF , PIK3CA , and AKT1 mutations in formalin-fixed, paraffin-embedded tissues. PMID: 22938585 Ref: Possibility of molecular targeting therapy for the treatment of cancer of unknown primary origin by analysis of intracellular signaling molecules. PMID: 22969927 Ref: PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes. PMID: 22983389 Ref: Molecular dissection of premalignant colorectal lesions reveals early onset of the CpG island methylator phenotype. PMID: 22995252 Ref: Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. PMID: 23034650 Ref: Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. PMID: 23045248 Ref: KRAS mutation testing in metastatic colorectal cancer. PMID: 23066310 Ref: Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. PMID: 23094721 Ref: Survey of KRAS, BRAF and PIK3CA mutational status in 209 consecutive Italian colorectal cancer patients. PMID: 23125007 Ref: [Predictive biomarkers for anti-EGFR antibodies]. PMID: 23152013 Ref: [Detection of KRAS, BRAF, PIK3CA and EGFR gene mutations in colorectal carcinoma]. PMID: 23157825 Ref: Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel. PMID: 23213241 Ref: Tumor phosphatidylinositol-3-kinase signaling and development of metastatic disease in locally advanced rectal cancer. PMID: 23226389 Ref: [A study of the relationship between the mutation of PIK3CA, PTEN and the occurrence of liver metastasis of colorectal cancer: survival analysis]. PMID: 23302486 Ref: Mutational analysis of key EGFR pathway genes in Chinese breast cancer patients. PMID: 23317280 |
Ref: Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer. PMID: 22638623 Ref: Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations. PMID: 22647972 Ref: KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials. PMID: 22672749 Ref: A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction. PMID: 22798500 Ref: Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer. PMID: 22936063 Ref: PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma. PMID: 22955107 Ref: Aldose reductase inhibition prevents colon cancer growth by restoring phosphatase and tensin homolog through modulation of miR-21 and FOXO3a. PMID: 22978663 Ref: HSP27 expression in primary colorectal cancers is dependent on mutation of KRAS and PI3K/AKT activation status and is independent of TP53. PMID: 22982087 Ref: KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines. PMID: 23015072 Ref: Association between genomic alterations and metastatic behavior of colorectal cancer identified by array-based comparative genomic hybridization. PMID: 23073979 Ref: Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. PMID: 23136247 Ref: Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome. PMID: 23158210 Ref: Use of multivariate analysis to suggest a new molecular classification of colorectal cancer. PMID: 23165447 Ref: Potential biomarker for aspirin use in colorectal cancer therapy. PMID: 23207797 Ref: Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. PMID: 23251002 Ref: Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. PMID: 23281932 Ref: Synthesis and biological evaluation of novel coumarin-pyrazoline hybrids endowed with phenylsulfonyl moiety as antitumor agents. PMID: 23291120 Ref: Aspirin, PIK3CA mutation, and colorectal-cancer survival. PMID: 23323913 Ref: Aspirin, PIK3CA mutation, and colorectal-cancer survival. PMID: 23323914 Ref: Aspirin, PIK3CA mutation, and colorectal-cancer survival. PMID: 23323915 Ref: Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease. PMID: 23347191 Ref: Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. PMID: 23374602 Ref: Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial. PMID: 23412099 Ref: Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy? PMID: 23429431 Ref: Energy deprivation by silibinin in colorectal cancer cells: a double-edged sword targeting both apoptotic and autophagic machineries. PMID: 23445752 Ref: Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. PMID: 23471846 Ref: Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer. PMID: 23475782 Ref: Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancer. PMID: 23520486 Ref: High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer. PMID: 23548132 Ref: Oncogenic mutations and microsatellite instability phenotype predict specific anatomical subsite in colorectal cancer patients. PMID: 23572025 Ref: Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation. PMID: 23580570 Ref: Stage III & IV colon and rectal cancers share a similar genetic profile: a review of the Oregon Colorectal Cancer Registry. PMID: 23592171 Ref: mTOR inhibition elicits a dramatic response in PI3K-dependent colon cancers. PMID: 23593290 Ref: Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery. PMID: 23617638 Ref: PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer. PMID: 23633456 Ref: The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. PMID: 23660947 Ref: MACC1 mRNA levels predict cancer recurrence after resection of colorectal cancer liver metastases. PMID: 23665971 Ref: A novel fully automated molecular diagnostic system (AMDS) for colorectal cancer mutation detection. PMID: 23671647 Ref: Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. PMID: 23725851 Ref: Descriptive profile of PIK3CA-mutated colorectal cancer in postmenopausal women. PMID: 23728594 Ref: Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy +/- cetuximab. PMID: 23741067 Ref: Overexpression of hypoxia inducible factor-1 alpha is an independent risk factor for recurrence after curative resection of colorectal liver metastases. PMID: 23748663 Ref: Methylation levels of LINE-1 in primary lesion and matched metastatic lesions of colorectal cancer. PMID: 23764749 Ref: Selenate induces epithelial-mesenchymal transition in a colorectal carcinoma cell line by AKT activation. PMID: 23769801 Ref: PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival. PMID: 23785428 Ref: Aspirin use and risk of colorectal cancer according to BRAF mutation status. PMID: 23800934 Ref: Molecular analysis of appendiceal mucinous cystadenoma and rectal adenocarcinoma in a patient with urothelial carcinoma: a case report. PMID: 23809582 Ref: Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation. PMID: 23826249 Ref: Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer Center. PMID: 23876834 Ref: Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. PMID: 23878352 Ref: Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis. PMID: 23934607 Ref: Pattern of clinically relevant mutations in consecutive series of Russian colorectal cancer patients. PMID: 23943423 Ref: Morphological change of a laterally spreading rectal tumor over a short period. PMID: 23957258 Ref: [Association of epithermal growth factor receptor expression and its downstream gene mutation status with radiosensitivity of colorectal carcinoma cell lines in vitro]. PMID: 23980047 Ref: Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia. PMID: 23992303 Ref: Simultaneous identification of 36 mutations in KRAS codons 61 and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit. PMID: 24006859 Ref: Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations. PMID: 24042191 Ref: Epigenetic and genetic features of 24 colon cancer cell lines. PMID: 24042735 Ref: Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. PMID: 24062397 Ref: Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. PMID: 24092809 Ref: BRAF V600E is a determinant of sensitivity to proteasome inhibitors. PMID: 24107445 Ref: Association of candidate single nucleotide polymorphisms with somatic mutation of the epidermal growth factor receptor pathway. PMID: 24152305 Ref: PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival. PMID: 24156022 Ref: Aspirin therapy for colorectal cancer with PIK3CA mutation: simply complex! PMID: 24166520 Ref: A small cog in a big wheel: PIK3CA mutations in colorectal cancer. PMID: 24231451 Ref: Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. PMID: 24231454 Ref: Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine. PMID: 24339949 Ref: Somatic gene mutations in African Americans may predict worse outcomes in colorectal cancer. PMID: 24440976 Ref: Aspirin for colorectal cancer with PIK3CA mutations: the rising of the oldest targeted therapy? PMID: 25332957 |
Ref: Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. PMID: 23542178 Ref: PIK3CA and APC mutations are synergistic in the development of intestinal cancers. PMID: 23708654 Ref: Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. PMID: 23792451 Ref: Phosphatidylinositol-3-kinase pathway aberrations in gastric and colorectal cancer: meta-analysis, co-occurrence and ethnic variation. PMID: 23960014 Ref: Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer. PMID: 24006244 Ref: PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17. PMID: 24218517 Ref: Physiological expression of the PI3K-activating mutation Pik3ca(H1047R) combines with Apc loss to promote development of invasive intestinal adenocarcinomas in mice. PMID: 24320611 Ref: Tumor heterogeneity revealed by KRAS, BRAF, and PIK3CA pyrosequencing: KRAS and PIK3CA intratumor mutation profile differences and their therapeutic implications. PMID: 24352906 Ref: DNA testing and molecular screening for colon cancer. PMID: 24355100 Ref: MicroRNA-375 inhibits colorectal cancer growth by targeting PIK3CA. PMID: 24440701 Ref: DNA content analysis of colorectal cancer defines a distinct 'microsatellite and chromosome stable' group but does not predict response to radiotherapy. PMID: 24456329 Ref: Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS. PMID: 24500024 Ref: Mutational analysis and clinical correlation of metastatic colorectal cancer. PMID: 24500602 Ref: SMARCB1 (INI1)-negative rhabdoid carcinomas of the gastrointestinal tract: clinicopathologic and molecular study of a highly aggressive variant with literature review. PMID: 24503755 Ref: Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer. PMID: 24576621 Ref: Methylation epigenotypes and genetic features in colorectal laterally spreading tumors. PMID: 24590867 Ref: EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab. PMID: 24595598 Ref: [Perspective of personalized (precise) cancer therapy based on predictive biomarkers]. PMID: 24597345 Ref: Comparative genomic analysis of primary and synchronous metastatic colorectal cancers. PMID: 24599305 Ref: [Aspirin and PIK3CA mutation in colorectal cancer]. PMID: 24622874 Ref: PIK3CA in Colorectal Cancer. PMID: 24624362 Ref: Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencing. PMID: 24664487 Ref: Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. PMID: 24676216 Ref: ZIC1 is a putative tumor suppressor in thyroid cancer by modulating major signaling pathways and transcription factor FOXO3a. PMID: 24684457 Ref: Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer. PMID: 24687028 Ref: The frequencies and clinical implications of mutations in 33 kinase-related genes in locally advanced rectal cancer: a pilot study. PMID: 24700299 Ref: Genetic mechanisms in interval colon cancers. PMID: 24705641 Ref: The Emerging Role of NRAS Mutations in Colorectal Cancer Patients Selected for Anti-EGFR Therapies. PMID: 24758538 Ref: Pyrosequencing evaluation of low-frequency KRAS mutant alleles for EGF receptor therapy selection in metastatic colorectal carcinoma. PMID: 24799053 Ref: Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic study. PMID: 24800948 Ref: Impact of genetic profiles on the efficacy of anti-EGFR antibodies in metastatic colorectal cancer with KRAS mutation. PMID: 24839940 Ref: Comprehensive molecular characterisation of hereditary non-polyposis colorectal tumours with mismatch repair proficiency. PMID: 24841217 Ref: Clinical relevance of alterations in quantity and quality of plasma DNA in colorectal cancer patients: based on the mutation spectra detected in primary tumors. PMID: 24841357 Ref: The evolution of our molecular understanding of colorectal cancer: what we are doing now, what the future holds, and how tumor profiling is just the beginning. PMID: 24857065 Ref: Mutations of KRAS and PIK3CA as independent predictors of distant metastases in colorectal cancer. PMID: 24861917 Ref: Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection. PMID: 24863535 Ref: Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review. PMID: 24885062 Ref: Predicted 25(OH)D score and colorectal cancer risk according to vitamin D receptor expression. PMID: 24920642 Ref: WNT signaling and distant metastasis in colon cancer through transcriptional activity of nuclear beta-Catenin depend on active PI3K signaling. PMID: 24930890 Ref: 'Druggable' alterations detected by Ion Torrent in metastatic colorectal cancer patients. PMID: 24932229 Ref: Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions. PMID: 24935274 Ref: Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. PMID: 24942275 Ref: Whole genome sequencing reveals potential targets for therapy in patients with refractory KRAS mutated metastatic colorectal cancer. PMID: 24943349 Ref: Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations. PMID: 24947927 Ref: Influence of CHIEF pathway genes on gene expression: a pathway approach to functionality. PMID: 24959314 Ref: ERBB3 knockdown induces cell cycle arrest and activation of Bak and Bax-dependent apoptosis in colon cancer cells. PMID: 24970817 Ref: SMO expression in colorectal cancer: associations with clinical, pathological, and molecular features. PMID: 25023548 Ref: Small bowel adenocarcinomas complicating Crohn's disease are associated with dysplasia: a pathological and molecular study. PMID: 25029614 Ref: Current approaches for predicting a lack of response to anti-EGFR therapy in KRAS wild-type patients. PMID: 25032217 Ref: Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma. PMID: 25073438 Ref: Sporadic early-onset colorectal cancer is a specific sub-type of cancer: a morphological, molecular and genetics study. PMID: 25083765 Ref: Distinct molecular features of different macroscopic subtypes of colorectal neoplasms. PMID: 25093594 Ref: Development of siRNA payloads to target KRAS-mutant cancer. PMID: 25100204 Ref: IGF2 differentially methylated region hypomethylation in relation to pathological and molecular features of serrated lesions. PMID: 25110432 Ref: Relationship between aspirin use after diagnosis of colorectal cancer and patient survival: a meta-analysis of observational studies. PMID: 25180765 Ref: Tumor LINE-1 methylation level and microsatellite instability in relation to colorectal cancer prognosis. PMID: 25190725 Ref: KRAS and PIK3CA mutation frequencies in patient-derived xenograft models of pancreatic and colorectal cancer are reflective of patient tumors and stable across passages. PMID: 25197873 Ref: Biological and molecular effects of small molecule kinase inhibitors on low-passage human colorectal cancer cell lines. PMID: 25309914 Ref: Colorectal cancer in Chinese patients: current and emerging treatment options. PMID: 25336973 Ref: Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer. PMID: 25337237 Ref: BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients. PMID: 25367198 Ref: Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation. PMID: 25379021 Ref: Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. PMID: 25392179 Ref: Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancer. PMID: 25444464 Ref: XIAP-targeting drugs re-sensitize PIK3CA-mutated colorectal cancer cells for death receptor-induced apoptosis. PMID: 25501831 Ref: Genomic profiling of patient-derived colon cancer xenograft models. PMID: 25526474 Ref: The influence of the CHIEF pathway on colorectal cancer-specific mortality. PMID: 25541970 Ref: PIK3CA and PIK3CB expression and relationship with multidrug resistance in colorectal carcinoma. PMID: 25550888 Ref: Molecular pathology of colorectal cancer. PMID: 25693079 |
Ref: Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis. PMID: 25239119 Ref: Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model. PMID: 25242168 Ref: Identification of novel mutations by exome sequencing in African American colorectal cancer patients. PMID: 25250560 Ref: Prognostic significance and molecular features of signet-ring cell and mucinous components in colorectal carcinoma. PMID: 25326395 Ref: Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9. PMID: 25326806 Ref: Role of p38 MAPK in enhanced human cancer cells killing by the combination of aspirin and ABT-737. PMID: 25388762 Ref: Portrait of the PI3K/AKT pathway in colorectal cancer. PMID: 25450577 Ref: RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer. PMID: 25491172 Ref: MicroRNAs associated with initiation and progression of colonic polyp: a feasibility study. PMID: 25496852 Ref: Target-enriched next-generation sequencing reveals differences between primary and secondary ovarian tumors in formalin-fixed, paraffin-embedded tissue. PMID: 25545608 Ref: Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation. PMID: 25549537 Ref: Quinazoline based small molecule exerts potent tumour suppressive properties by inhibiting PI3K/Akt/FoxO3a signalling in experimental colon cancer. PMID: 25554016 Ref: A pathway-centric survey of somatic mutations in Chinese patients with colorectal carcinomas. PMID: 25617745 Ref: Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer. PMID: 25623215 Ref: Inter- and intra-tumor profiling of multi-regional colon cancer and metastasis. PMID: 25623536 Ref: Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases. PMID: 25639985 Ref: PIK3CA mutations predict recurrence in localized microsatellite stable colon cancer. PMID: 25641861 Ref: EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab. PMID: 25663927 Ref: Novel molecular insights from routine genotyping of colorectal carcinomas. PMID: 25683705 Ref: Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. PMID: 25688736 Ref: Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors. PMID: 25695693 Ref: Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. PMID: 25706875 Ref: Evaluating patient-derived colorectal cancer xenografts as preclinical models by comparison with patient clinical data. PMID: 25712343 Ref: AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants. PMID: 25714871 Ref: Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer. PMID: 25742472 Ref: Distinctive Spatiotemporal Stability of Somatic Mutations in Metastasized Microsatellite-stable Colorectal Cancer. PMID: 25786087 Ref: Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis. PMID: 25797243 Ref: Identification of KRAS and PIK3CA but not BRAF mutations in patients with gastric cancer. PMID: 25815786 Ref: A functional variant at miR-520a binding site in PIK3CA alters susceptibility to colorectal cancer in a Chinese Han population. PMID: 25834816 Ref: Polymorphic GT dinucleotide repeat in the PIK3CA gene and risk of colorectal cancer. PMID: 25835181 Ref: Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. PMID: 25838391 Ref: Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. PMID: 25851630 Ref: Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer. PMID: 25884297 Ref: Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib. PMID: 25889309 Ref: Neoadjuvant chemotherapy in locally advanced colon cancer. A phase II trial. PMID: 25920359 Ref: Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab. PMID: 25943333 Ref: A specific KRAS codon 13 mutation is an independent predictor for colorectal cancer metachronous distant metastases. PMID: 25973306 Ref: Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. PMID: 25979833 Ref: Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer. PMID: 25993166 Ref: PIK3CA Somatic Mutation Status in Relation to Patient and Tumor Factors in Racial/Ethnic Minorities with Colorectal Cancer. PMID: 25994739 Ref: [Molecular analysis of sporadic colon cancer]. PMID: 26005817 Ref: Amplicon sequencing of colorectal cancer: variant calling in frozen and formalin-fixed samples. PMID: 26010451 Ref: Genetic Alterations in Colorectal Cancer Have Different Patterns on 18F-FDG PET/CT. PMID: 26018692 Ref: Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models. PMID: 26019172 Ref: PIK3CA Amplification Is Common in Left Side-Tubular Adenomas but Uncommon Sessile Serrated Adenomas Exclusively with KRAS Mutation. PMID: 26019684 Ref: Identification and characterization of RET fusions in advanced colorectal cancer. PMID: 26078337 Ref: Genetic mutations in human rectal cancers detected by targeted sequencing. PMID: 26134512 Ref: Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models. PMID: 26136684 Ref: Computed tomography assessment of early response to neoadjuvant therapy in colon cancer. PMID: 26183044 Ref: Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer. PMID: 26216840 Ref: Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers. PMID: 26226847 Ref: Diagnostic yield of targeted next generation sequencing in various cancer types: an information-theoretic approach. PMID: 26227479 Ref: Durable recurrence-free survival after pneumonectomy for late lung metastasis from rectal cancer: case report with genetic and epigenetic analyses. PMID: 26231173 Ref: HER2 activating mutations are targets for colorectal cancer treatment. PMID: 26243863 Ref: MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer. PMID: 26272063 Ref: Colon Tumors with the Simultaneous Induction of Driver Mutations in APC, KRAS, and PIK3CA Still Progress through the Adenoma-to-carcinoma Sequence. PMID: 26276752 Ref: [Biochip detection of KRAS, BRAF, and PIK3CA somatic mutations in colorectal cancer patients]. PMID: 26299862 Ref: Wild-type APC predicts poor prognosis in microsatellite-stable proximal colon cancer. PMID: 26305864 Ref: KRAS, NRAS, BRAF mutation comparison of endoscopic and surgically removed primary CRC paired samples: is endoscopy biopsy material adequate for molecular evaluation? PMID: 26325103 Ref: Precision medicine in colorectal cancer: the molecular profile alters treatment strategies. PMID: 26327923 Ref: High Prevalence and Clinical Relevance of Genes Affected by Chromosomal Breaks in Colorectal Cancer. PMID: 26375816 Ref: Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. PMID: 26392102 Ref: Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers. PMID: 26404261 Ref: Postdiagnostic intake of one-carbon nutrients and alcohol in relation to colorectal cancer survival. PMID: 26423386 Ref: Rapid targeted somatic mutation analysis of solid tumors in routine clinical diagnostics. PMID: 26435479 Ref: Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts. PMID: 26439693 Ref: Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092. PMID: 26469692 Ref: Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan. PMID: 26486455 Ref: Clinical detection and categorization of uncommon and concomitant mutations involving BRAF. PMID: 26498038 Ref: A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations. PMID: 26512781 Ref: Mutational profiling of colorectal cancers with microsatellite instability. PMID: 26517354 Ref: Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. PMID: 26553611 Ref: Assessing the potential value of long interspersed element-1 hypomethylation in colorectal cancer: evidence from retrospective studies. PMID: 26604793 Ref: Biomarker-directed Targeted Therapy in Colorectal Cancer. PMID: 26609516 Ref: Mutation of the PIK3CA gene as a prognostic factor in patients with colorectal cancer. PMID: 26622684 Ref: Multi-Scale Genomic, Transcriptomic and Proteomic Analysis of Colorectal Cancer Cell Lines to Identify Novel Biomarkers. PMID: 26678268 Ref: Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases. PMID: 26691448 Ref: Impact of somatic mutations on patterns of metastasis in colorectal cancer. PMID: 26697197 Ref: Roles of genetic variants in the PI3K/PTEN pathways in susceptibility to colorectal carcinoma and clinical outcomes treated with FOLFOX regimen. PMID: 26722535 Ref: The H1047R point mutation in p110 alpha changes the morphology of human colon HCT116 cancer cells. PMID: 27551473 |
Ref: Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer. PMID: 26001389 Ref: Tankyrase Inhibition Blocks Wnt/beta-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. PMID: 26224873 Ref: Correlation between DPYD gene variation and KRAS wild type status in colorectal cancer. PMID: 26281864 Ref: RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies. PMID: 26350096 Ref: Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial. PMID: 26350752 Ref: MicroRNA MIR21 and T Cells in Colorectal Cancer. PMID: 26419959 Ref: Mutation Spectra of Common Cancer-Associated Genes in Different Phenotypes of Colorectal Carcinoma Without Distant Metastasis. PMID: 26471487 Ref: Prognostic Utility of Molecular Factors by Age at Diagnosis of Colorectal Cancer. PMID: 26490308 Ref: NDRG4 stratifies the prognostic value of body mass index in colorectal cancer. PMID: 26515606 Ref: Next-Generation Sequencing of Matched Primary and Metastatic Rectal Adenocarcinomas Demonstrates Minimal Mutation Gain and Concordance to Colonic Adenocarcinomas. PMID: 26536055 Ref: Survival Benefit of Exercise Differs by Tumor IRS1 Expression Status in Colorectal Cancer. PMID: 26577117 Ref: Prediagnosis Plasma Adiponectin in Relation to Colorectal Cancer Risk According to KRAS Mutation Status. PMID: 26598515 Ref: Genetic heterogeneity in synchronous colorectal cancers impacts genotyping approaches and therapeutic strategies. PMID: 26650777 Ref: PIK3CA Mutation, Aspirin Use after Diagnosis and Survival of Colorectal Cancer. A Systematic Review and Meta-analysis of Epidemiological Studies. PMID: 26712086 Ref: Targeting the PI3K signaling pathway in KRAS mutant colon cancer. PMID: 26715098 Ref: KRAS mutation in lung metastases from colorectal cancer: prognostic implications. PMID: 26715198 Ref: Loss of CDH1 (E-cadherin) expression is associated with infiltrative tumour growth and lymph node metastasis. PMID: 26742007 Ref: PIK3CA and PIK3CB silencing by RNAi reverse MDR and inhibit tumorigenic properties in human colorectal carcinoma. PMID: 26747178 Ref: BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells. PMID: 26802026 Ref: Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent. PMID: 26820797 Ref: Integrative modeling of multi-omics data to identify cancer drivers and infer patient-specific gene activity. PMID: 26864072 Ref: Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS. PMID: 26869800 Ref: Molecular characterization of colorectal cancer patients and concomitant patient-derived tumor cell establishment. PMID: 26909603 Ref: Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin. PMID: 26915040 Ref: Genotyping of colorectal cancer for cancer precision medicine: Results from the IPH Center for Molecular Pathology. PMID: 26917275 Ref: Value of KRAS, BRAF, and PIK3CA Mutations and Survival Benefit from Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis. PMID: 26925640 Ref: MicroRNA MIR21 (miR-21) and PTGS2 Expression in Colorectal Cancer and Patient Survival. PMID: 26957558 Ref: Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology. PMID: 26968814 Ref: Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells. PMID: 26983878 Ref: BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis. PMID: 26991109 Ref: Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases. PMID: 26991344 Ref: Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. PMID: 27002107 Ref: RAS mutation is a prognostic biomarker in colorectal cancer patients with metastasectomy. PMID: 27004837 Ref: The Prognostic Influence of BRAF Mutation and other Molecular, Clinical and Laboratory Parameters in Stage IV Colorectal Cancer. PMID: 27033063 Ref: Aspirin and Colorectal Cancer Prevention and Treatment: Is It for Everyone? PMID: 27069437 Ref: Prognostic impact of mutation profiling in patients with stage II and III colon cancer. PMID: 27074743 Ref: miRs-134 and -370 function as tumor suppressors in colorectal cancer by independently suppressing EGFR and PI3K signalling. PMID: 27095166 Ref: Aspirin in the Treatment of Cancer: Reductions in Metastatic Spread and in Mortality: A Systematic Review and Meta-Analyses of Published Studies. PMID: 27096951 Ref: A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma. PMID: 27118441 Ref: Clinical significance of frequent somatic mutations detected by high-throughput targeted sequencing in archived colorectal cancer samples. PMID: 27146902 Ref: Metformin in combination with 5-fluorouracil suppresses tumor growth by inhibiting the Warburg effect in human oral squamous cell carcinoma. PMID: 27210058 Ref: The Inositide Signaling Pathway As a Target for Treating Gastric Cancer and Colorectal Cancer. PMID: 27242542 Ref: ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. PMID: 27246726 Ref: Recurrent, truncating SOX9 mutations are associated with SOX9 overexpression, KRAS mutation, and TP53 wild type status in colorectal carcinoma. PMID: 27248473 Ref: Comparison of KRAS mutation status between primary tumor and metastasis in Chinese colorectal cancer patients. PMID: 27270901 Ref: Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance. PMID: 27283768 Ref: The role of aspirin in colorectal cancer chemoprevention. PMID: 27289249 Ref: Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes. PMID: 27302833 Ref: Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer. PMID: 27321283 Ref: Molecular pathological classification of colorectal cancer. PMID: 27325016 Ref: Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow. PMID: 27332557 Ref: [New molecular classification of colorectal cancer, pancreatic cancer and stomach cancer: Towards "a la carte" treatment?]. PMID: 27345450 Ref: Tumor LINE-1 methylation level and colorectal cancer location in relation to patient survival. PMID: 27391152 Ref: Challenging a dogma: co-mutations exist in MAPK pathway genes in colorectal cancer. PMID: 27401719 Ref: Highly sensitive detection of the PIK3CA (H1047R) mutation in colorectal cancer using a novel PCR-RFLP method. PMID: 27405731 Ref: CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer. PMID: 27435270 Ref: Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysis. PMID: 27436848 Ref: Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells. PMID: 27461218 Ref: Somatic mutation profiles in primary colorectal cancers and matching ovarian metastases: Identification of driver and passenger mutations. PMID: 27499925 Ref: Molecular differences in the microsatellite stable phenotype between left-sided and right-sided colorectal cancer. PMID: 27509333 Ref: Experimental verification of a predicted novel microRNA located in human PIK3CA gene with a potential oncogenic function in colorectal cancer. PMID: 27511117 Ref: Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy. PMID: 27570430 Ref: Specific inhibition of p110alpha subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers. PMID: 27602501 Ref: Oncogene Mutations in Colorectal Polyps Identified in the Norwegian Colorectal Cancer Prevention (NORCCAP) Screening Study. PMID: 27656095 Ref: Genomic characterization of liver metastases from colorectal cancer patients. PMID: 27662660 Ref: Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer. PMID: 27682134 Ref: Genomic profiling of stage II and III colon cancers reveals APC mutations to be associated with survival in stage III colon cancer patients. PMID: 27729614 Ref: Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study. PMID: 27737711 Ref: MicroRNA let-7, T Cells, and Patient Survival in Colorectal Cancer. PMID: 27737877 Ref: Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing. PMID: 27756406 Ref: Oncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancer. PMID: 27777877 Ref: Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer. PMID: 27835884 Ref: Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer. PMID: 27863403 Ref: Favorable control of advanced colon adenocarcinoma with severe bone marrow metastasis: A case report. PMID: 27900088 Ref: Molecular spectrum of KRAS, NRAS, BRAF, PIK3CA, TP53, and APC somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern. PMID: 28078112 Ref: Functional genomics reveals that tumors with activating phosphoinositide 3-kinase mutations are dependent on accelerated protein turnover. PMID: 28087713 Ref: [A Case of Metastatic Colon Cancer Dramatically Affected by Anti-EGFR Antibody Therapy]. PMID: 28133136 Ref: Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience. PMID: 28356789 Ref: Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial. PMID: 28848656 Ref: Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases. PMID: 28949453 |
Ref: Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. PMID: 27196573 Ref: Paired Primary and Metastatic Tumor Analysis of Somatic Mutations in Synchronous and Metachronous Colorectal Cancer. PMID: 27384156 Ref: FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation. PMID: 27399335 Ref: Colorectal cancer heterogeneity and targeted therapy: Clinical implications, challenges and solutions for treatment resistance. PMID: 27578007 Ref: Comparison of the molecular profile of brain metastases from colorectal cancer and corresponding primary tumors. PMID: 27578453 Ref: Gene heterogeneity in metastasis of colorectal cancer to the lung. PMID: 27590223 Ref: Colorectal carcinomas with submucosal invasion (pT1): analysis of histopathological and molecular factors predicting lymph node metastasis. PMID: 27713420 Ref: Examining the impact of regular aspirin use and PIK3CA mutations on survival in stage 2 colon cancer. PMID: 27800646 Ref: EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer. PMID: 27879995 Ref: Morphological characterization of colorectal cancers in The Cancer Genome Atlas reveals distinct morphology-molecular associations: clinical and biological implications. PMID: 27982025 Ref: Targeted exome sequencing reveals distinct pathogenic variants in Iranians with colorectal cancer. PMID: 28002797 Ref: Analysis of KRAS, NRAS, PIK3CA, and BRAF mutational profile in poorly differentiated clusters of KRAS-mutated colon cancer. PMID: 28025078 Ref: Molecular explorations of substituted 2-(4-phenylquinolin-2-yl) phenols as phosphoinositide 3-kinase inhibitors and anticancer agents. PMID: 28054203 Ref: Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients. PMID: 28068936 Ref: Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer. PMID: 28106826 Ref: Cudraflavone C Induces Tumor-Specific Apoptosis in Colorectal Cancer Cells through Inhibition of the Phosphoinositide 3-Kinase (PI3K)-AKT Pathway. PMID: 28107519 Ref: QMC-PCRx: a novel method for rapid mutation detection. PMID: 28153952 Ref: Aspirin-Induced Chemoprevention and Response Kinetics Are Enhanced by PIK3CA Mutations in Colorectal Cancer Cells. PMID: 28154202 Ref: Whole-exome sequencing identified mutational profiles of high-grade colon adenomas. PMID: 28179590 Ref: Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA Mutations. PMID: 28184015 Ref: KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior. PMID: 28188750 Ref: ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer. PMID: 28199979 Ref: Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study. PMID: 28222664 Ref: Construction of a multiplex mutation hot spot PCR panel: the first step towards colorectal cancer genotyping on the GS Junior platform. PMID: 28243320 Ref: Detection of PIK3CA Mutations in Plasma DNA of Colorectal Cancer Patients by an Ultra-Sensitive PNA-Mediated PCR. PMID: 28247181 Ref: Dietary glycemic and insulin scores and colorectal cancer survival by tumor molecular biomarkers. PMID: 28268248 Ref: Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis. PMID: 28280620 Ref: Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie. PMID: 28280626 Ref: Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance). PMID: 28327908 Ref: Mitochondrial DNA alteration in primary and metastatic colorectal cancer: Different frequency and association with selected clinicopathological and molecular markers. PMID: 28345467 Ref: APC and PIK3CA Mutational Cooperativity Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colorectal Liver Metastases. PMID: 28379870 Ref: Tumor SQSTM1 (p62) expression and T cells in colorectal cancer. PMID: 28405513 Ref: Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status. PMID: 28406723 Ref: PIK3CA mutation and colorectal cancer precision medicine. PMID: 28423591 Ref: FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. PMID: 28424412 Ref: Oncogenic beta-catenin and PIK3CA instruct network states and cancer phenotypes in intestinal organoids. PMID: 28442534 Ref: Risk factors for brain metastases in patients with metastatic colorectal cancer. PMID: 28447565 Ref: Evaluation of PTGS2 Expression, PIK3CA Mutation, Aspirin Use and Colon Cancer Survival in a Population-Based Cohort Study. PMID: 28448072 Ref: Feasibility of multiplexed gene mutation detection in plasma samples of colorectal cancer patients by mass spectrometric genotyping. PMID: 28459822 Ref: Local recurrences at the anastomotic area are clonally related to the primary tumor in sporadic colorectal carcinoma. PMID: 28476018 Ref: Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer. PMID: 28513830 Ref: Targeted sequencing-based analyses of candidate gene variants in ulcerative colitis-associated colorectal neoplasia. PMID: 28524162 Ref: Emergence of CD26+ Cancer Stem Cells with Metastatic Properties in Colorectal Carcinogenesis. PMID: 28545226 Ref: A Specific Mutational Signature Associated with DNA 8-Oxoguanine Persistence in MUTYH-defective Colorectal Cancer. PMID: 28551381 Ref: Genomic Profiling of Small-Bowel Adenocarcinoma. PMID: 28617917 Ref: Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights. PMID: 28618197 Ref: Oncogene mutation profile predicts tumor regression and survival in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and radical surgery. PMID: 28671043 Ref: Molecular and Clinicopathological Differences by Age at the Diagnosis of Colorectal Cancer. PMID: 28678173 Ref: Heterogeneity in the colorectal primary tumor and the synchronous resected liver metastases prior to and after treatment with an anti-EGFR monoclonal antibody. PMID: 28685087 Ref: A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution. PMID: 28746882 Ref: Squirrel Primer-Based PCR Assay for Direct and Targeted Sanger Sequencing of Short Genomic Segments. PMID: 28785174 Ref: Measurement of Telomere Length in Colorectal Cancers for Improved Molecular Diagnosis. PMID: 28850092 Ref: Tumor expression of calcium sensing receptor and colorectal cancer survival: Results from the nurses' health study and health professionals follow-up study. PMID: 28856682 Ref: Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations. PMID: 28859058 Ref: Implementation and utilization of the molecular tumor board to guide precision medicine. PMID: 28915716 Ref: The Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation. PMID: 28928860 Ref: EGFR pathway subgroups in Chilean colorectal cancer patients, detected by mutational and expression profiles, associated to different clinicopathological features. PMID: 28936923 Ref: Tumor Heterogeneity Predicts Metastatic Potential in Colorectal Cancer. PMID: 28939741 Ref: Major challenges related to tumor biological characteristics in accurate mutation detection of colorectal cancer by next-generation sequencing. PMID: 28942013 Ref: Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer. PMID: 29038297 Ref: Acquired somatic TP53 or PIK3CA mutations are potential predictors of when polyps evolve into colorectal cancer. PMID: 29069792 Ref: POLE somatic mutations in advanced colorectal cancer. PMID: 29072370 Ref: Establishing a colorectal cancer liver metastasis patient-derived tumor xenograft model for the evaluation of personalized chemotherapy. PMID: 29094026 Ref: Tumor-biopsy stratification based on mTOR-pathway activity and functional mutations in the upstream genes PIK3CA and PTEN. PMID: 29137436 Ref: Aspirin exerts high anti-cancer activity in PIK3CA-mutant colon cancer cells. PMID: 29152088 Ref: Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. PMID: 29156800 Ref: Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer. PMID: 29169325 Ref: Comprehensive genomic sequencing detects important genetic differences between right-sided and left-sided colorectal cancer. PMID: 29212173 Ref: Robust RNA-based in situ mutation detection delineates colorectal cancer subclonal evolution. PMID: 29222441 Ref: Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine. PMID: 29285234 Ref: Integration of pharmacology, molecular pathology, and population data science to support precision gastrointestinal oncology. PMID: 29552640 |
Ref: Insulin-like growth factor-1 activates different catalytic subunits p110 of PI3K in a cell-type-dependent manner to induce lipogenesis-dependent epithelial-mesenchymal transition through the regulation of ADAM10 and ADAM17. PMID: 28819788 Ref: Optimal detection of clinically relevant mutations in colorectal carcinoma: sample pooling overcomes intra-tumoral heterogeneity. PMID: 29027537 Ref: Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience. PMID: 29128266 Ref: [Aspirin and colorectal cancer]. PMID: 29153543 Ref: Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. PMID: 29180604 Ref: Molecular profiling and genome-wide analysis based on somatic copy number alterations in advanced colorectal cancers. PMID: 29230882 Ref: Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial. PMID: 29254887 Ref: Phase II Study of Panitumumab in RAS Wild-Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater. PMID: 29259073 Ref: Locked Nucleic Acid Technology for Highly Sensitive Detection of Somatic Mutations in Cancer. PMID: 29304903 Ref: Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. PMID: 29316426 Ref: Mutations of key driver genes in colorectal cancer progression and metastasis. PMID: 29322354 Ref: Significance of Liquid Biopsy for Monitoring and Therapy Decision of Colorectal Cancer. PMID: 29367069 Ref: Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer. PMID: 29380640 Ref: Clinical Impact of PI3K/BRAF Mutations in RAS Wild Metastatic Colorectal Cancer: Meta-analysis Results. PMID: 29388061 Ref: Phosphatidylinositol 3-Kinase alpha-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. PMID: 29401002 Ref: Copy number profiles of paired primary and metastatic colorectal cancers. PMID: 29423054 Ref: PIK3CA and TP53 mutations predict overall survival of stage II/III colorectal cancer patients. PMID: 29434452 Ref: mir-106a regulates cell proliferation and apoptosis of colon cancer cells through targeting the PTEN/PI3K/AKT signaling pathway. PMID: 29435057 Ref: Molecular characterization of ERBB2-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive cases. PMID: 29438965 Ref: Molecular characterization of colorectal adenomas with and without malignancy reveals distinguishing genome, transcriptome and methylome alterations. PMID: 29453410 Ref: First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients. PMID: 29470838 Ref: Colorectal cancer cell-derived exosomes containing miR-10b regulate fibroblast cells via the PI3K/Akt pathway. PMID: 29496262 Ref: The molecular landscape of synchronous colorectal cancer reveals genetic heterogeneity. PMID: 29546405 Ref: Expression of factors and key components associated with the PI3K signaling pathway in colon cancer. PMID: 29552187 Ref: Surface Enhanced Raman Spectroscopy (SERS) for the Multiplex Detection of Braf, Kras, and Pik3ca Mutations in Plasma of Colorectal Cancer Patients. PMID: 29556349 Ref: Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies. PMID: 29588308 Ref: Racial Disparities in the Molecular Landscape of Cancer. PMID: 29599344 Ref: A Network Pharmacology Approach to Uncover the Multiple Mechanisms of Hedyotis diffusa Willd. on Colorectal Cancer. PMID: 29619072 Ref: Differential clinicopathological and molecular features within late-onset colorectal cancer according to tumor location. PMID: 29632645 Ref: Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients. PMID: 29666387 Ref: Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients. PMID: 29705968 Ref: Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer. PMID: 29718453 Ref: Hotspot KRAS exon 2 mutations in CD166 positive colorectal cancer and colorectal adenoma cells. PMID: 29755662 Ref: Clinical application of targeted next-generation sequencing for colorectal cancer patients: a multicentric Belgian experience. PMID: 29755687 Ref: Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis. PMID: 29771009 Ref: Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses. PMID: 29793804 Ref: Identification of different mutational profiles in cancers arising in specific colon segments by next generation sequencing. PMID: 29844865 Ref: Simultaneous identification of clinically relevant single nucleotide variants, copy number alterations and gene fusions in solid tumors by targeted next-generation sequencing. PMID: 29854313 Ref: TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas. PMID: 29900052 Ref: Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer. PMID: 29908105 Ref: Circulating tumor DNA detectable in early- and late-stage colorectal cancer patients. PMID: 29914973 Ref: Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence. PMID: 29937183 Ref: The landscape of somatic mutation in sporadic Chinese colorectal cancer. PMID: 29937994 Ref: Liquid biopsy in mice bearing colorectal carcinoma xenografts: gateways regulating the levels of circulating tumor DNA (ctDNA) and miRNA (ctmiRNA). PMID: 29941002 Ref: Gene promoter and exon DNA methylation changes in colon cancer development - mRNA expression and tumor mutation alterations. PMID: 29945573 Ref: PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer. PMID: 29970892 Ref: Differences in gene mutations according to gender among patients with colorectal cancer. PMID: 29976257 Ref: Activation of WNT/beta-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations. PMID: 29978469 Ref: Downregulation of PIK3CA via antibody-esiRNA-complexes suppresses human xenograft tumor growth. PMID: 30001368 Ref: Combination of BEZ235 and Metformin Has Synergistic Effect on Cell Viability in Colorectal Cancer Cells. PMID: 30023463 Ref: Genomic alterations accompanying tumour evolution in colorectal cancer: tracking the differences between primary tumours and synchronous liver metastases by whole-exome sequencing. PMID: 30029640 Ref: Discovery of an Orally Bioavailable Dual PI3K/mTOR Inhibitor Based on Sulfonyl-Substituted Morpholinopyrimidines. PMID: 30034607 Ref: Molecular characteristics of colorectal cancer in a Middle Eastern population in a single institution. PMID: 30078023 Ref: Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study. PMID: 30085422 Ref: Difference Between Left-Sided and Right-Sided Colorectal Cancer: A Focused Review of Literature. PMID: 30116425 Ref: The gene mutational discrepancies between primary and paired metastatic colorectal carcinoma detected by next-generation sequencing. PMID: 30171333 Ref: Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases. PMID: 30202242 Ref: Vitamin D status after colorectal cancer diagnosis and patient survival according to immune response to tumour. PMID: 30219720 Ref: Liquid Biopsy to Identify Actionable Genomic Alterations. PMID: 30231331 Ref: The Amount of Bifidobacterium Genus in Colorectal Carcinoma Tissue in Relation to Tumor Characteristics and Clinical Outcome. PMID: 30243655 Ref: Positive association of PIK3CA mutation with KRAS mutation but not BRAF mutation in colorectal cancer suggests co-selection is gene specific but not pathway specific. PMID: 30361395 |